New study tracks lupus drug anifrolumab in daily practice across 10+ countries

NCT ID NCT06314282

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 31 times

Summary

This study follows 200 adults with systemic lupus erythematosus (SLE) who are starting anifrolumab for the first time as part of their usual care. Researchers will track disease activity, skin symptoms, fatigue, and quality of life over time using standard medical assessments. The goal is to see how well the drug works in real-world settings across multiple countries.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Aktobe, Kazakhstan
Research Site
RECRUITING

Almaty, Kazakhstan
Research Site
RECRUITING

Astana, Kazakhstan
Research Site
RECRUITING

Pavlodar, Kazakhstan
Research Site
RECRUITING

Semey, Kazakhstan
Research Site
RECRUITING

Shymkent, Kazakhstan

Conditions

Explore the condition pages connected to this study.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)